Results 211 to 220 of about 634,412 (379)

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch   +9 more
wiley   +1 more source

A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Bepirovirsen, an antisense oligonucleotide in development for the treatment of chronic hepatitis B virus (HBV) infection, is administered from glass vials as a subcutaneous (SC) injection by healthcare professionals (HCPs). A ready‐to‐use prefilled syringe (PFS) assembled with a safety syringe device (SSD) has been developed to make ...
Amir S. Youssef   +15 more
wiley   +1 more source

Hypersensitivity to romidepsin

open access: yesJournal of the American Academy of Dermatology, 2014
Jenneé Rommel   +4 more
openaire   +2 more sources

Profiling a Neo‐Antigen‐Driven Immune Response in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Study of the KLH Challenge Model

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Novel compounds targeting the adaptive immune system are commonly initially investigated in healthy volunteers (HV). HV frequently lack constitutively expressed drug‐target engagement biomarkers, complicating the evaluation of pharmacological activity. The keyhole limpet hemocyanin (KLH) neo‐antigen challenge elicits a controlled immune response in HV ...
Micha N. Ronner   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy